HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IND Warning Has US Supplement Firm ISO Answers

Vietnamese Refugee Founded RAAS In 1980, 5 Years After Beginning US Health/Wellness Career

Executive Summary

RAAS Nutritionals tells FDA “it proceeded without an IND because it believed that if it was legally able to sell its nutritional supplements ... it should be able to test and observe the effects of those supplements without an IND.”

You may also be interested in...

Microbiome Therapy Firm’s COVID-19 Medical Food Research Landed On US FDA’s Drug Study Menu

Medical food is “for the specific dietary management of a disease or condition for which distinctive nutritional requirements … are established by medical evaluation,” but no distinctive nutritional requirements are established for COVID-19, FDA says. Kaleido says in SEC filing that it “intends to continue with its plans to submit an IND for KB109 in support of future clinical research.”

CDB Supplements Next On FDA's Investigational New Drug Warning List

The agency published warnings to four firms marketing supplements containing CDB ingredients with claims to treat or cure cancer made in statements including testimonials on their websites for products varying from oils, capsules, tinctures and lotions to snacks including gummies and lollipops.

In $4.4 Trillion ‘Global Wellness Economy’ Of 2020, Supplement Sales Accounted For $137.7 Billion

Global Wellness Institute’s vitamins and supplements, healthy-labeled foods and beverages and weight loss products and services overall showed 3.6% sales growth to $945bn from 2019 to 2020, according to institute’s latest report.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts